Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Promoter-specific transcription of insulin-like growth factor-II in epithelial ovarian cancer.

Promoter-specific transcription of insulin-like growth factor-II in epithelial ovarian cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Promoter-specific transcription of insulin-like growth factor-II in epithelial ovarian cancer. Abstract Text:

    lingeng luLingeng Lu,dionyssios katsarosDionyssios Katsaros,andrew wileyAndrew Wiley,i a rigault de la longraisI A Rigault de la Longrais,manuela puopoloManuela Puopolo,peter schwartzPeter Schwartz,herbert yuHerbert Yu,

    OBJECTIVES: The IGF-II gene has four promoters (P1-P4); each initiates promoter-specific transcription. Studies have shown that IGF-II promoters normally active during fetal growth, but silent in postnatal life, are reactivated in cancer. In a previous study, we found IGF-II transcription evaluated at a common translated region was associated with ovarian cancer progression. This study was conducted to further determine which IGF-II promoters were responsible for the association. METHODS: Promoter-specific transcription at each IGF-II promoter was analyzed in 201 ovarian tumor samples using quantitative RT-PCR. Cox regression analysis was performed to determine the association of IGF-II promoter-specific expression with patient survival. RESULTS: P3 and P4 transcripts were detected more frequently and at significantly higher levels than the transcripts of P1 and P2. P3 and P4 transcripts were strongly correlated with the common IGF-II translated region and were significantly higher in patients with late stage disease, large residual tumor, suboptimal debulking or serous histology compared to those with early stage, small residual tumor, optimal debulking or non-serous histology. Survival analysis showed that patients with high P3 or P4 expression had a 2-fold increase in risk for death compared to those with low P3 or P4. These associations remained significant after adjustment for patient age at surgery, disease stage, tumor grade and histology. P1 and P2 transcripts, however, were not associated with disease characteristics or survival. CONCLUSIONS: These findings suggest that IGF-II transcription from P3 and P4 promoters is important in ovarian cancer and evaluation of IGF-II promoter-specific transcription may have clinical implications in ovarian cancer prognosis and treatment.

    Promoter-specific transcription of insulin-like growth factor-II in epithelial ovarian cancer. Publishing Authors By Initials

    l luL Lu,d katsarosD Katsaros,a wileyA Wiley,ia rigault de la longraisIA Rigault de la Longrais,m puopoloM Puopolo,p schwartzP Schwartz,h yuH Yu,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    Promoter-specific transcription of insulin-like growth factor-II in epithelial ovarian cancer. Journal Published:

    PUBLICATION TYPE: Research Support, Non-U.S. Gov

    Journal: Gynecologic oncology

    VOLUME: 103

    Page Numbers: 990-5

    Journal Abbreviation: Gynecol. Oncol.

    ISSN: 0090-8258

    DAY: 21

    MONTH: 07

    YEAR: 2006

    Promoter-specific transcription of insulin-like growth factor-II in epithelial ovarian cancer. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 365304

    Promoter-specific transcription of insulin-like growth factor-II in epithelial ovarian cancer. Keywords Mesh Terms:

    KEYWORDS: Reverse Transcriptase Polymerase Chain R

    MESH TERMS: analysis

    Chemical & Substance for Abstract: Promoter-specific transcription of insulin-like growth factor-II in epithelial ovarian cancer. Information

    Substance Name: Insulin-Like Growth Factor II

    Registry Number: 67763-97-7

    Grant and Affiliation Information for Promoter-specific transcription of insulin-like growth factor-II in epithelial ovarian cancer.

    AFFILIATION: Department of Epidemiology, Yale Cancer Center, Yale University School of Medicine, 60 College Street, New Haven, CT 06520-8034, USA.

    Country: United States

    United States Research PublicationUnited States Research Publication

    AGENCY: United States NIA

    GRANT: R01AG21392

    ACRONYM: AG

    MEDLINETA: Gynecol Oncol

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Promoter-specific transcription of insulin-like growth factor-II in epithelial ovarian cancer Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News